

Special Issue

Neurodegenerative Diseases: Modern Diagnostic Techniques and Emerging Therapeutic Perspectives

Message from the Guest Editor

Alzheimer's disease (AD) is the most common neurodegenerative disease, but its causes remain largely unclear. Genetic risk variants identified so far show either small effect sizes or with larger effects but are extremely rare in frequency among the population. AD's missing heritability remains therefore extensive, which has been attributed, at least partially, to mechanisms not currently investigated by traditional "single-locus" approaches, i.e., testing a single genetic variant and/or gene. In this Special Issue, we will focus on "multi-locus" approaches, i.e., the role of polygenic risk scores (PRS, i.e., the summation of multiple risk loci across the genome) and epistasis (i.e., interaction between genetic loci) in the context of AD and its endophenotypes.

Guest Editor

Prof. Dr. Mariarosa Anna Beatrice Melone

1. Department of Medical and Surgical Advanced Sciences, Second Division of Neurology, Center for Rare Neurological and Neuromuscular Diseases & Inter University Center for Research in Neurosciences, University of Campania Luigi Vanvitelli, Naples, Italy
2. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA

Deadline for manuscript submissions

closed (20 December 2022)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/82418

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))